SBFM (Sunshine Biopharma) Probability of Financial Distress (%): 34.41% (As of Jun. 26, 2026)


SBFM Sunshine Biopharma Inc SBFM
34 GF Score
Price $2.17
GF Value $7.10
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma Probability of Financial Distress (%)?

Sunshine Biopharma SBFM +1.87% 34 Probability of Financial Distress (%) is 34.41% as of Jun. 26, 2026. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.10 (Possible Value Trap). The stock has 4 warning signs investors should review.

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Sunshine Biopharma's Probability of Financial Distress (%) is 34.41%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Sunshine Biopharma  (NAS:SBFM) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Sunshine Biopharma Probability of Financial Distress (%) Related Terms


SBFM vs SNOA, CTTH, BUDZ: Probability of Financial Distress (%) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma Probability of Financial Distress (%) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Probability of Financial Distress (%) falls into.


SBFM
34GF Score
Sunshine Biopharma Inc SBFM
Probability of Financial Distress (%) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Biopharma Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-0.64

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=34.41%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).

What does a Probability of Financial Distress (%) of 34.41% mean?
Sunshine Biopharma (SBFM) has a Probability of Financial Distress (%) of 34.41% as of Jun. 26, 2026.
Is Sunshine Biopharma's Probability of Financial Distress (%) too high?
Sunshine Biopharma's current Probability of Financial Distress (%) is 34.41%. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Probability of Financial Distress (%) compare to SNOA and CTTH?
Sunshine Biopharma's Probability of Financial Distress (%) of 34.41% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Probability of Financial Distress (%) for a Drug Manufacturers company?
A good Probability of Financial Distress (%) depends on the Drug Manufacturers industry context. However, Probability of Financial Distress (%) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Probability of Financial Distress (%) mean?
A high Probability of Financial Distress (%) can signal that a stock is expensive relative to its fundamentals. Sunshine Biopharma's current Probability of Financial Distress (%) is 34.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.10, compared to a current price of $2.17 — trading 69.4% below its estimated fair value. The current Probability of Financial Distress (%) is 34.41%. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Probability of Financial Distress (%) calculated?
Probability of Financial Distress (%) is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current Probability of Financial Distress (%) is 34.41% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Biopharma (SBFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued. The current stock price of $2.17 is trading 69.4% below its estimated GF Value™ of $7.10. GuruFocus considers Sunshine Biopharma to be Possible Value Trap.

Key valuation signals for SBFM:

  • Probability of Financial Distress (%): 34.41%
  • GF Value™: $7.10 vs. price of $2.17 (69.4% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sunshine Biopharma Business Description

Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFM

Probability of Financial Distress (%) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.17
Price
$7.10
GF Value